Share on StockTwits

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 13,111,252 shares, a growth of 15.8% from the March 31st total of 11,321,300 shares, American Banking reports. Based on an average trading volume of 2,856,424 shares, the short-interest ratio is presently 4.6 days. Approximately 13.5% of the company’s shares are sold short.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 in a research note on Tuesday, March 4th. Analysts at Zacks downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. ACADIA Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $26.33.

ACADIA Pharmaceuticals (NASDAQ:ACAD) opened at 20.13 on Thursday. ACADIA Pharmaceuticals has a 1-year low of $11.26 and a 1-year high of $32.00. The stock has a 50-day moving average of $22.6 and a 200-day moving average of $23.76. The company’s market cap is $1.839 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Thursday, February 27th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.01. Analysts expect that ACADIA Pharmaceuticals will post $-0.55 EPS for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.